TuHURA Biosciences Receives FDA IND Clearance For TBS-2025 In AML

TuHURA Biosciences (HURA) received FDA clearance for its IND application for TBS-2025, a VISTA-inhibiting monoclonal antibody for AML. The Phase 1b study will evaluate TBS-2025 in relapsed/refractory mutNPM1 AML patients. Preclinical data showed increased survival in AML models. HURA stock is up 1.71%, trading at $2.09.

Original reporting
Published Sep 14, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 4:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$HURA
Bullish
high confidence
Mentioned
$HURA
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$HURABullishHigh
01

Why it matters

The IND clearance removes a regulatory hurdle, allowing the company to begin human testing, which is a pivotal step toward potential market approval and revenue.

02

Market read

The announcement is likely to generate buying interest in HURA and may influence sentiment toward similar early‑stage oncology stocks.

03

What to watch

Funding runway and competition from other AML immunotherapies could limit long‑term upside.

Relevance 8/10Novelty 8/10Timing: on announcement

Background

TuHURA Biosciences (HURA) is a micro‑cap biotech developing VISTA‑inhibiting antibodies for AML and other hematologic cancers.

Company-level read

Ticker impact

$HURABullishHigh confidence
Context

FDA cleared TuHURA Biosciences' IND for TBS-2025, enabling a Phase 1b trial in AML patients.

Expected impact

Potential short-term upside as investors price in clinical progress; volatility may increase on trial updates.

Evidence & confidence

Regulatory approval is a material, non‑recurring event that often lifts biotech stocks, especially for a micro‑cap with limited prior data.

Market effects

Highlights growing interest in VISTA‑targeted immunotherapies within the oncology sector.

May boost investor sentiment toward US‑listed biotech firms focusing on AML.

Adds to the pipeline of novel checkpoint inhibitors, relevant for global oncology investors.

Counterpoint

If early trial data are modest, the stock could face steep downside despite the IND clearance.

Key entities

  • TuHURA Biosciences

    US‑listed biotech developing TBS‑2025 for AML.

  • FDA

    U.S. Food and Drug Administration granting IND clearance.

Related articles

$HURAMed

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., Nov. 13, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance

$HURAMed

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences (NASDAQ: HURA) reported Q3 2026 results, highlighting progress in its immuno-oncology programs. The company shared early data from its IFx-2.0 study with Keytruda, showing durable responses in Merkel cell carcinoma patients. It also received FDA clearance for a Phase 1b study of its VISTA-inhibiting antibody, TBS-2025, in a subset of AML. TuHURA has $1.9M in cash and access to a $50M credit facility.

$HURAMedAI 8/10

TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences reported early responses in a study of its immunotherapy IFx-2.0 for deep-seated Merkel cell cancer. Preliminary results showed potential for use with checkpoint inhibitors, with five of eight patients in a prior study achieving durable responses. The company is conducting a Phase III trial comparing IFx-2.0 plus pembrolizumab to placebo, with enrollment expected to complete by Q3 or Q4 2024. TuHURA aims to discuss regulatory options with the FDA if data remains favorable.

$HURAHighAI 8/10

TuHURA reports tumor responses in 3-patient cancer trial

TuHURA Biosciences (HURA) reported partial tumor responses in 3 patients from a trial of IFx-2.0 combined with Keytruda for metastatic Merkel Cell Carcinoma. The Phase 1b/2a trial aims to enroll 9 patients and assesses safety and feasibility. The company is also conducting a Phase 3 trial. HURA hosted a webcast to discuss the initial data.

$HURALow

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

TuHURA Biosciences (NASDAQ:HURA) received a U.S. patent for its Delta Opioid Receptor (DOR) technology, covering uses in cancer treatments, including ADCs and cellular immunotherapies. The patent, valid until 2043, aims to enhance cancer immunotherapy effectiveness by targeting MDSCs. TuHURA is advancing preclinical models for blood-related cancers like AML and MDS.